E01T0727 Human Triosephosphate isomerase ELISA kit
The Human Triosephosphate isomerase ELISA kit can be used to identify samples from the human species. Triosephosphate isomerase can also be called phosphotriose isomerase, triose phosphoisomerase, triose phosphate mutase, D-glyceraldehyde-3-phosphate ketol-isomerase.
Product Information | |
Cat. No. | E01T0727 |
Product Name | Human Triosephosphate isomerase ELISA kit |
Species | Human |
Product Size | 48 Tests / 96 Tests |
Concentration | 100-2500 pg/ml |
Sensitivity | 1.0 pg/ml |
Principal | Competitive ELISA |
Sample Volume | 100 ul |
Sample Type | Serum, plasma, cell culture supernatants, body fluid and tissue homogenate |
Assay Time | 90 minutes |
Platform | Microplate Reader |
Conjugate | HRP |
Detection Method | Colorimetric |
Storage | 2-8°C |
Kit Components | ||
MATERIALS | SPECIFICATION | QUANTITY |
MICROTITER PLATE | 96 wells | stripwell |
ENZYME CONJUGATE | 6.0 mL | 1 vial |
STANDARD A (0.5mL) | 0 pg/mL | 1 vial |
STANDARD B (0.5mL) | 100 pg/mL | 1 vial |
STANDARD C (0.5mL) | 250 pg/mL | 1 vial |
STANDARD D (0.5mL) | 500 pg/mL | 1 vial |
STANDARD E (0.5mL) | 1000 pg/mL | 1 vial |
STANDARD F (0.5mL) | 2500 pg/mL | 1 vial |
SUBSTRATE A | 6 mL | 1 vial |
SUBSTRATE B | 6 mL | 1 vial |
STOP SOLUTION | 6 mL | 1 vial |
WASH SOLUTION (100 x) | 10 mL | 1 vial |
BALANCE SOLUTION | 3 mL | 1 vial |
Principle of the Assay |
TPI1 ELISA kit uses an anti-TPI1 antibody and an TPI1-HRP conjugate in a competitive enzyme immunoassay method. TPI1-HRP conjugate is incubated with the assay sample and buffer in a pre-coated plate for one hour. The wells are decanted and washed five times when the incubation period is over. The HRP enzyme substrate is then incubated in the wells. The result of the enzyme-substrate reaction is a complex that is blue in hue. The process is finally stopped by adding a stop solution, causing the solution to turn yellow. In a microplate reader, the color intensity is measured spectrophotometrically at 450 nm. Due to competition for the anti-TPI1 antibody binding site between TPI1 from samples and TPI1-HRP conjugate, the intensity of the color is inversely proportional to the concentration of TPI1. Since the number of sites is limited, as more sites are occupied by TPI1 from the sample, fewer sites are left to bind TPI1-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The TPI1 concentration in each sample is interpolated from this standard curve. |
Coefficient of Variance | Intra Variation% ＜10% | |
Inter Variation% ＜12% | ||
Recovery | 95-102% | |
Linearity | Diluent Ratio | Range % |
1:2 | 93-105 | |
1:4 | 88-106 | |
1:8 | 86-108 | |
Specificity/Cross-reactivity | No significant cross-reactivity or interference between TPI1 and analogues was observed. | |
E01T0727 has been referenced in the below publications：
cAMP-PKA-CaMKII signaling pathway is involved in aggravated cardiotoxicity during Fuzi and Beimu Combination Treatment of Experimental Pulmonary Hypertension.
Related Bluegene Biotech Products
BlueGene Biotech News
